Find Clinical Trial

Home » Find Clinical Trials » Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not to metformine or to an a-glucosidase inhibitor during the fast of the Ramadan in type 2 diabetic patients. A 5 to 8 months, national, multicentre, open study. Efficacité et tolérance du gliclazide LM (30 à 120 mg/j per os) associé ou non à la metformine ou à un inhibiteur des a-glucosidases pendant le jeûne du Ramadan chez des patients diabétiques de type 2. Etude nationale, multicentrique de 5 à 8 mois de traitement en ouvert.

Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not to metformine or to an a-glucosidase inhibitor during the fast of the Ramadan in type 2 diabetic patients. A 5 to 8 months, national, multicentre, open study. Efficacité et tolérance du gliclazide LM (30 à 120 mg/j per os) associé ou non à la metformine ou à un inhibiteur des a-glucosidases pendant le jeûne du Ramadan chez des patients diabétiques de type 2. Etude nationale, multicentrique de 5 à 8 mois de traitement en ouvert.

← Back

Study Phase	Phase 3

Therapeutic Area	Metabolism

Indication	Diabetes - Type II

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	GLICLAZIDE, S005702

Active Substance Code	S005702

Protocol Code	CL3-05702-014

EudraCT Code	2006-006754-10

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.